The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for ...

The BBC's probe into Diary of a CEO has followed an increase in emphasis on health topics by Bartlett that, according to the ...

Editas ended the third quarter with cash reserves of around $256 million, down from $318 million three months earlier. It ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

While 2025 remains an unknown quantity, it’s clear that fundraisers and investors see the value in visiting London in ...

Private equity group Carlyle has joined forces with other investors on a €900 million-plus recapitalisation of UK drugmaker ...

Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the treatment of patients with polyneuropathy associated with transthyretin ...

Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US. The company has received a complete response letter (CRL) from the FDA for a ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure. The European Commission revoked the conditional ...

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug. Tasfygo (tasurgratinib succinate; formerly E7090), a small-molecule ...

Overall, DoE is a valuable approach to improving the quality and efficacy of the final product, streamlining the process, and ...